You are in: eMedicine Specialties > Radiology > CHEST Aspergillosis, ThoracicArticle Last Updated: May 1, 2008AUTHOR AND EDITOR INFORMATIONAuthor: Ali Nawaz Khan, MBBS, FRCS, FRCP, FRCR, LRCP, Chairman of Medical Imaging, Professor of Radiology, NGHA, King Fahad National Guard Hospital, King Abdulaziz Medical City, Riyadh, Saudi Arabia Ali Nawaz Khan is a member of the following medical societies: American Institute of Ultrasound in Medicine, Radiological Society of North America, Royal College of Physicians, Royal College of Physicians and Surgeons of the United States, Royal College of Radiologists, and Royal College of Surgeons of England Coauthor(s): Sarah Al Ghanem, MBBS, Consulting Staff, Department of Medical Imaging, King Fahad National Guard Hospital, Riyadh, Saudi Arabia; Klaus L Irion, MD, PhD, Consulting Staff, The Cardiothoracic Centre Liverpool NHS Trust, The Royal Liverpool University Hospital, UK; Sumaira MacDonald, MBChB, PhD, MRCP, FRCR, Lecturer, Sheffield University Medical School; Endovascular Fellow, Sheffield Vascular Institute; Carolyn M Allen, MB, BCh, MRCP, FRCR, CCST, Consultant Radiologist, Department of Clinical Radiology, North Manchester General Hospital, UK Editors: Satinder P Singh, MD, Associate Professor of Radiology, Chief of Cardiopulmonary Radiology, Director of Cardiac CT, Director of Combined Cardiopulmonary and Abdominal Radiology, Department of Radiology, University of Alabama at Birmingham; Bernard D Coombs, MB, ChB, PhD, Consulting Staff, Department of Specialist Rehabilitation Services, Hutt Valley District Health Board, New Zealand; Eric J Stern, MD, Professor of Radiology, Adjunct Professor of Medicine, Adjunct Professor of Medical Education and Biomedical Informatics, University of Washington School of Medicine; Director of Thoracic Imaging, Harborview Medical Center; Associate Medical Staff, Seattle Cancer Care Alliance; Robert M Krasny, MD, Consulting Staff, Department of Radiology, The Angeles Clinic and Research Institute; Barry H Gross, MD, Professor, Department of Radiology, University of Michigan Medical School; Professor, University of Michigan Cancer Center Author and Editor Disclosure Synonyms and related keywords: pulmonary aspergillosis, Aspergillus fumigatus, A fumigatus, allergic bronchopulmonary aspergillosis, ABPA, saprophytic aspergillosis, aspergilloma, chronic necrotizing aspergillosis, airway-invasive aspergillosis, semi-invasive aspergillosis, angioinvasive aspergillosis, finger-in-glove sign, tree-in-bud sign, air-crescent sign INTRODUCTIONBackgroundPulmonary aspergillosis is a spectrum of mycotic diseases caused by the Aspergillus species, usually Aspergillus fumigatus.1, 2 This intensely antigenic and ubiquitous soil fungus is commonly found in the sputum of healthy individuals. However, in susceptible hosts, its ability to invade the arteries and veins facilitates its hematogenous spread. The development of disease and its histologic, clinical, and radiologic manifestations depend on the virulence and number of spores inhaled and, more importantly, on the patient's immune status. Pulmonary aspergillosis may take any of 4 forms1, 2:
For excellent patient education resources, visit eMedicine's Lung and Airway Center and Asthma Center. Also, see eMedicine's patient education articles Asthma, Allergy, and Acute Respiratory Distress Syndrome. PathophysiologyA fumigatus exists in 2 forms: (1) conidiophores, the reproductive forms that produce and release thousands of spores, and (2) hyphae, which represent mature spores that are characterized by a 45º dichotomous branching pattern (see Images 1 and 2). The fungus grows widely in soil, water, and decaying vegetable or animal material. The spores are readily inhaled, and the fungus is a common commensal organism in the upper respiratory tract. Most patients with pulmonary aspergillosis have either an underlying preexisting chronic lung disease or impaired immunity. Examples of preexisting chronic lung disease include bronchiectasis, chronic obstructive lung disease (COPD), and tuberculosis. Impaired immunity secondary to alcoholism, advanced age, poorly controlled diabetes mellitus, underlying malignancy, cirrhosis, malnutrition, sepsis, organ transplantation, or acquired immunodeficiency syndrome (AIDS), for example.3, 4, 5, 6, 7, 8 ABPA represents a hypersensitivity reaction to A fumigatus in patients with long-standing asthma or cystic fibrosis. Excessive mucus production in association with impaired ciliary function leads to mucoid impaction of the airways. The plugs of inspissated mucus contain A fumigatus and eosinophils, but the organisms remain within the bronchial lumen; this feature differentiates ABPA from invasive aspergillosis. Precipitating antibodies incite a type I acute hypersensitivity reaction with the subsequent release of immunoglobulin E (IgE) and immunoglobulin G (IgG). Immune complexes and inflammatory cells are then deposited within the bronchial mucosa. This deposition produces tissue necrosis and eosinophilic infiltrate, a type III reaction, and results in damage to the bronchial wall with the subsequent development of bronchiectasis. Patients may cough up mucus plugs, from which hyphal elements can be cultured or observed at microscopy. The primary diagnostic criteria for ABPA include the following:
The primary radiologic criteria include fixed or transitory pulmonary infiltrates and central bronchiectasis as a late manifestation.9, 10 A set of secondary criteria can sometimes be applied; these include the presence of A fumigatus mycelia in the sputum, the expectoration of brown sputum plugs, and a delayed cutaneous reaction to A fumigatus antigen. ABPA can be staged by using the following clinical and radiologic criteria:
In the saprophytic form (ie, aspergilloma), noninvasive colonization of a preexisting cavity, cyst, bulla, or ectatic bronchus occurs. The most common underlying conditions are tuberculosis, sarcoidosis, and bronchiectasis. Others include cystic fibrosis, ankylosing spondylitis, bronchogenic cysts, pneumoconiosis, pulmonary sequestration, cavitating malignancy, and pneumatoceles secondary to Pneumocystis carinii pneumonia. Chronic necrotizing aspergillosis, or semi-invasive aspergillosis, is an indolent disease that affects patients with mild immunosuppression due to chronic debilitating illness, particularly those with COPD. Other recognized predisposing illnesses include alcoholism, advanced age, and prolonged steroid administration. Bronchiolitis and bronchopneumonia develop, with slowly progressive cavitating consolidation predominating in the upper lobes (see Images 7 and 8). This consolidation may be indistinguishable from tuberculosis. Histologically, a proliferation of organisms within the alveolar spaces, intra-alveolar hemorrhage, and bronchial wall invasion that leads to tissue necrosis with microabscess formation are present, but no angioinvasion is observed. Invasive aspergillosis is the most common fungal pulmonary infection in severely immunocompromised patients, particularly those with reticuloses. Transplant recipients are also at particular risk.6, 7 The spores proliferate in the airways; this proliferation leads to transbronchial angioinvasion that causes hemorrhagic infarction. These areas may become cavitated and contain a devitalized sequestrum of infected lung; moreover, these areas can mimic a mycetoma. Also, the fungus can disseminate systemically in approximately 33% of cases and affect the heart, brain, kidneys, liver, spleen, thyroid, and gastrointestinal tract. A fumigatus may also infect the pleura, causing an empyema in patients with pulmonary tuberculosis or bronchopleural fistulae. Occasionally, A fumigatus may secondarily infect an existing bacterial empyema. FrequencyUnited StatesApproximately 1-2% of asthmatic patients and 10% of patients with cystic fibrosis have ABPA. Aspergillomas are reported to account for 0.02% of hospital admissions. The precise incidence of chronic necrotizing aspergillosis is unknown, but it is thought to be increasing. The number of patients with invasive aspergillosis has substantially increased. One of the reasons for this increasing incidence is the development of new intensive chemotherapy for leukemia, lymphoma, and myeloma, as well as the increasing numbers of solid organ transplantations. Invasive pulmonary aspergillosis (IPA) is reported in 5% of bone marrow transplant recipients, 3-9% of renal transplant recipients, and 1-5% of heart and/or lung or liver transplant recipients. InternationalAspergillomas are complications in 15-20% of patients with lung cavities 2 cm or larger. The incidence of invasive aspergillosis in AIDS patients is 1-12% worldwide. In the United Kingdom, the incidence is estimated to be 4-5%. Mortality/MorbidityThe mortality and morbidity rates with pulmonary aspergillosis depend on the type of disease.1, 2, 11
SexThe male-to-female incidence is 3:1. AgePulmonary aspergillosis mostly affects adults aged 20-90 years. AnatomyMost mycetomas derive their blood supply from the bronchial arteries. The bronchial arteries not only perfuse the bronchi but also contribute blood supply to the mid esophagus, diaphragm, mediastinal visceral pleura, and vasa vasorum of the aorta and pulmonary arteries. In addition, an occasional contribution to the thoracic spinal cord and the myocardium may be present. Knowledge of the bronchial arterial supply is important to prevent potentially catastrophic complications from arterial embolization of mycetomas. Clinical DetailsAcute clinical symptoms in ABPA include a low-grade fever, wheezing, productive cough, weight loss, malaise, headaches, and chest pain. Patients with ABPA also have a history of recurrent pneumonia. However, patients with aspergillomas are frequently asymptomatic. The most common clinical manifestation is hemoptysis, which may be life threatening. Symptoms of chronic necrotizing aspergillosis are often insidious at onset and nonspecific. These symptoms include a productive cough, fever, and constitutional upset, and they represent acute tracheobronchitis, bronchiolitis, or bronchopneumonia. Hemoptysis occurs in only 15% of patients. The angioinvasive form often causes nonspecific constitutional symptoms that make clinical diagnosis difficult. Patients often have an unremitting fever and pleuritic chest pain, which may mimic the findings of pulmonary embolism. Preferred ExaminationChest radiography is an initial examination of choice in patients with respiratory symptoms or suspected pulmonary disease.9, 10 However, many different causes of bronchiectasis, including ABPA, cannot be accurately diagnosed on chest radiographs. Also, radiographic features of pulmonary aspergillosis are generally nonspecific. Although the CT scan features of ABPA are not specific, the demonstration of bronchial dilatation, wall thickening, and centrilobular nodules in an asthmatic patient should suggest the diagnosis.14 The demonstration of a mobile mass within a cavity on supine and prone scans is virtually diagnostic of a mycetoma. The CT scan appearances of chronic necrotizing aspergillosis are also nonspecific, but CT does provide useful information regarding the extent of pulmonary disease and any associated pleural thickening. CT scan findings in angioinvasive aspergillosis are more specific, and the presence of nodules with a halo of ground-glass attenuation in the appropriate clinical setting allows confident diagnosis. Limitations of TechniquesThe appearances of the different types of thoracic aspergillosis are nonspecific, and a wide variety of lesions can mimic an aspergilloma. Examples of these include chronic necrotizing aspergillosis, angioinvasive aspergillosis, a tuberculous cavity with a Rasmussen aneurysm, cavitating bronchogenic carcinoma, lung abscess, hematoma, and P carinii pneumonia. Similarly, bronchial dilatation has a variety of causes. DIFFERENTIALSAsthma Bronchiectasis Bronchogenic Cyst Pneumonia, Pneumocystis Carinii Wegener Granulomatosis, Thoracic Other Problems to Be ConsideredDifferential diagnosis of cavitating upper lobe consolidation Amyloidosis Differential diagnosis of multiple pulmonary nodules Angioinvasive aspergillosis RADIOGRAPHFindingsIn ABPA, chest radiographic appearances include the following: (1) fleeting alveolar subsegmental or lobar infiltrates, which are usually bilateral (65%) and predominant in the upper lobes (50%); (2) central 1-2-cm ring shadows that represent varicose or cystic bronchiectasis; and (3) tram-link bronchial walls due to edema.1, 9, 10 The second-order bronchi may become plugged with mucus, and they may be visible as 2.5- to 6-cm long V- or Y-shaped branching tubular opacities that may grow over time and persist for months; this is the so-called finger-in-glove sign (see Image 3). Other features include lobar consolidation, atelectasis, postobstructive pneumonia, cavitation, air trapping, and parenchymal scarring or fibrosis, all of which are more pronounced in the upper lobes. Focal pleural thickening is also reported. Occasionally, mycetomas develop in ectatic bronchi. The characteristic chest radiographic appearance of an aspergilloma is that of a round or oval mass with the opacity of that of a soft-tissue mass. Often, an adjacent crescent-shaped air space (ie, the air-crescent sign) separates the fungal ball from the cavity wall (see Image 6). The mycetoma may rarely contain amorphous or rimlike calcification. The fungal ball is usually mobile and moves when the patient changes position. Often, extensive adjacent apical pleural thickening may be present; this finding may herald the development of the mycetoma. The radiologic manifestations of chronic necrotizing aspergillosis include unilateral or bilateral segmental areas of consolidation that are predominant in the upper lobes; frequently, these progress to cavitation. Pleural thickening is also a recognized feature. The most common chest radiographic appearance of invasive aspergillosis is that of patchy areas of consolidation, which progress despite the use of broad-spectrum antibiotics. Multiple nodules and peripheral wedged-shaped lesions due to hemorrhagic infarcts are also observed as the disease progresses. These frequently become cavitated, and an air-crescent sign that mimics mycetoma may also be observed. Degree of ConfidenceThe many different causes of bronchiectasis, including ABPA, cannot be accurately diagnosed with radiographs (see Differentials and Other Problems to Be Considered). Also, the radiographic features of pulmonary aspergillosis are generally nonspecific. False Positives/NegativesAn air-crescent sign may occur in the following: aspergilloma, chronic necrotizing aspergillosis, angioinvasive aspergillosis, tuberculous cavity with a Rasmussen aneurysm, cavitating bronchogenic carcinoma, lung abscess, hematoma, and P carinii pneumonia. CT SCANFindingsBronchiectasis and peribronchial thickening are the most common CT findings in ABPA.15, 16 Appearances tend to be more severe than in those of chronic uncomplicated asthma. ABPA typically involves the segmental and subsegmental bronchi, particularly those in the upper lobes. However, studies have shown that central bronchiectasis simply indicates long-standing severe inflammation; as a marker, it is not as specific for ABPA as was once thought. High-attenuating mucoid impaction, present in as many as 30% of patients, is a characteristic finding. Occasionally, lobar or segmental atelectasis may be a feature. Mucus plugging of the small airways can be observed on high-resolution CT scans, with resultant centrilobular nodularity and the tree-in-bud sign.14 Abnormalities of lung attenuation due to either mosaic perfusion or air trapping may also be identified. Scans obtained during expiration are useful in differentiating the findings in this instance. The CT scan and chest radiographic appearances of an aspergilloma are similar. The fungal ball is seen as a mass of soft-tissue attenuation within a pulmonary cavity. An anterior air crescent is visible if the patient is supine (see Images 6 and 8). The mobile nature of the mass can be demonstrated by scanning the patient in the prone position; the fungal ball falls to the dependent portion of the cavity. The cavity wall and adjacent pleura are frequently thickened, although these findings have been shown to resolve with successful treatment or with the spontaneous resolution of the infection. CT scan findings in chronic necrotizing aspergillosis include areas of chronic progressive peripheral consolidation, multiple nodular opacities, and low-attenuating masslike lesions. Abnormalities may be unilateral or bilateral, with an upper-lobe predilection. Cavitation is a common feature, and this often leads to the development of an intracavitary segment of sequestrated lung, which may mimic a mycetoma. Extension into the chest wall and mediastinum are also described. CT scan findings of angioinvasive aspergillosis include multiple nodules associated with a halo of ground-glass attenuation, which represents adjacent hemorrhage, and pleural-based wedge-shaped areas of consolidation, which correspond to hemorrhagic infarcts. The air-crescent sign may be observed in the recovery phase. Degree of ConfidenceAlthough the CT scan features of ABPA are not specific, the demonstration of bronchial dilatation, wall thickening, and centrilobular nodules in an asthmatic patient should suggest the diagnosis. The presence of ABPA is even more likely if bronchiectasis is severe, affects 3 or more lobes, and has a central distribution. Many pulmonary lesions become cavitated; however, the demonstration of a mobile mass within a cavity on supine and prone scans is virtually diagnostic of a mycetoma. CT scan appearances of chronic necrotizing aspergillosis are nonspecific, although CT scanning does provide accurate information regarding the distribution and extent of pulmonary disease and any associated pleural thickening. CT scan findings in angioinvasive aspergillosis are more specific, and the presence of nodules with a halo of ground-glass attenuation in the appropriate clinical setting allows confident diagnosis. False Positives/NegativesThe causes of false-positive and false-negative results are the same as those with chest radiography, as discussed in Radiograph, False Positives/Negatives. ANGIOGRAPHYFindingsSee Intervention, below. INTERVENTIONMassive hemoptysis may complicate a mycetoma. Surgical resection of the cavity is the treatment of choice. Contraindications to surgery include bilateral advanced lung disease, large transpleural blood vessels, failure to identify the bleeding site, and continued hemoptysis after previous surgery. Bronchial artery embolization is a valuable technique in patients with persistent hemoptysis who are not surgical candidates. Before bronchial artery embolization is attempted, angiography is performed to assess the bronchial arterial anatomy, nonbronchial systemic blood supply to the mycetoma, and presence and extent of any contribution of blood supply from the pulmonary artery (see Images 11 and 12). The technique involves selective bronchial artery catheterization with a femorovisceral 5-French end-hole catheter. After a preliminary bronchial angiogram study is performed, the catheter is securely inserted into the bronchial artery to be embolized. A coaxial catheter may be required for more selective and more distal placement. Various embolic agents can be used; the simplest material is polyvinyl alcohol (PVA), a particulate agent that is available in a variety of sizes. Because mycetomas can derive their blood supply from the intercostal arteries, the thyrocervical trunks and pulmonary arteries may also need to be selectively embolized (see Images 13-18). Percutaneous CT- or fluoroscopically guided intracavitary injection of a paste containing glycerin and amphotericin B or other fungal agents has been successful in the treatment of aspergillomas and chronic necrotizing aspergillosis. The fungal ball partially or completely resolved in 75% of patients. The intracavitary instillation of sodium or potassium iodide has also been used successfully in the treatment of hemoptysis in patients who are not surgical candidates.13 Medical/Legal Pitfalls
Related Medscape topic: Special Concerns
ACKNOWLEDGMENTSThe authors and editors of eMedicine gratefully acknowledge the contributions of previous coauthor Dr Hari Panigrahi to the development and writing of this article. MULTIMEDIA
REFERENCES
Aspergillosis, Thoracic excerpt Article Last Updated: May 1, 2008 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||